Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4527 Target Snapshot

TRAF2 and NCK-interacting protein kinase · SINGLE PROTEIN · Homo sapiens

1,217Compounds
244Assays
16Approved Drugs
987.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q9UKE5. Use UniProt Q9UKE5 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9UKE5 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats TRAF2 and NCK-interacting protein kinase as ChEMBL target CHEMBL4527, mapped to UniProt Q9UKE5. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
TRAF2 and NCK-interacting protein kinase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4527
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9UKE5
TRAF2 and NCK-interacting protein kinase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether TRAF2 and NCK-interacting protein kinase is the right protein anchor across sources, using UniProt Q9UKE5 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTRAF2 and NCK-interacting protein kinase
UniProt AccessionQ9UKE5
Component TypeProtein
Sequence Length1360 aa

TRAF2 and NCK-interacting protein kinase

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as TRAF2 and NCK-interacting protein kinase, mapped to UniProt Q9UKE5. Sequence length is 1360 aa.

Mapped IDQ9UKE5
Review nameTRAF2 and NCK-interacting protein kinase
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

16
Approved
11
Phase III
14
Phase II
7
Phase I
Assay Mix

Activity Type Distribution

IC50586.0
KI2.0
KD399.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4760558 9.92 IC50 0.12 Preclinical
CHEMBL4749291 9.89 IC50 0.13 Preclinical
CHEMBL4762464 9.74 IC50 0.18 Preclinical
CHEMBL4759123 9.72 IC50 0.19 Preclinical
CHEMBL4744045 9.68 IC50 0.21 Preclinical
CHEMBL4751494 9.68 IC50 0.21 Preclinical
CHEMBL4788405 9.66 IC50 0.22 Preclinical
CHEMBL4788976 9.66 IC50 0.22 Preclinical
CHEMBL4797452 9.64 IC50 0.23 Preclinical
CHEMBL4791330 9.6 IC50 0.25 Preclinical
Distribution

pChEMBL Value Distribution

27
5.0
53
5.5
62
6.0
78
6.5
136
7.0
102
7.5
114
8.0
19
8.5
17
9.0
12
9.5
pChEMBL
Approved Drugs

Approved Drugs

QUIZARTINIB
CHEMBL576982
Approved 2023
PACRITINIB
CHEMBL2035187
Approved 2022
NERATINIB
CHEMBL180022
Approved 2017
LENVATINIB
CHEMBL1289601
Approved 2015
NINTEDANIB
CHEMBL502835
Approved 2014
BOSUTINIB
CHEMBL288441
Approved 2012
AXITINIB
CHEMBL1289926
Approved 2012
PONATINIB
CHEMBL1171837
Approved 2012
PAZOPANIB
CHEMBL477772
Approved 2009
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

244
Total Assays
525
Tested Compounds
1
Assay Types
Binding — 244 assays, 525 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 169 476 7.3
cell-based format 38 20 6.4
assay format 21 2 7.5
subcellular format 15 27 6.4
tissue-based format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine